about
Roles of bioactive sphingolipids in cancer biology and therapeuticsRole of the autotaxin-lysophosphatidate axis in cancer resistance to chemotherapy and radiotherapyRegulation of Sphingolipid Biosynthesis by the Morphogenesis Checkpoint Kinase Swe1Stress responses from the endoplasmic reticulum in cancerIdentification and characterization of murine mitochondria-associated neutral sphingomyelinase (MA-nSMase), the mammalian sphingomyelin phosphodiesterase 5Species-specific ant brain manipulation by a specialized fungal parasite.Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapiesCeramide glycosylation catalyzed by glucosylceramide synthase and cancer drug resistance.LCL124, a cationic analog of ceramide, selectively induces pancreatic cancer cell death by accumulating in mitochondria.Yeast sphingolipids: recent developments in understanding biosynthesis, regulation, and function.P-glycoprotein antagonists confer synergistic sensitivity to short-chain ceramide in human multidrug-resistant cancer cells.Harnessing the power of yeast to elucidate the role of sphingolipids in metabolic and signaling processes pertinent to psychiatric disorders.Many ceramides.TGFβ-Mediated induction of SphK1 as a potential determinant in human MDA-MB-231 breast cancer cell bone metastasis.Sphingolipids in cancer: regulation of pathogenesis and therapy.Mass spectrometry images acylcarnitines, phosphatidylcholines, and sphingomyelin in MDA-MB-231 breast tumor models.Ceramide signaling in cancer and stem cells.Discovery of a Fluorinated Enigmol Analog with Enhanced in Vivo Pharmacokinetic and Anti-Tumor Properties.Downregulation of neutral ceramidase by gemcitabine: Implications for cell cycle regulation.Mammalian neutral sphingomyelinases: regulation and roles in cell signaling responses.Sphingolipids and expression regulation of genes in cancer.Implication of ceramide, ceramide 1-phosphate and sphingosine 1-phosphate in tumorigenesis.The role of sphingolipids in drug metabolism and transport.Allylic structures in cancer drugs and body metabolites that control cell life and death.Virus-mPLoc: a fusion classifier for viral protein subcellular location prediction by incorporating multiple sites.Therapeutic Strategies and Pharmacological Tools Influencing S1P Signaling and Metabolism.Targeting inhibitor 2 of protein phosphatase 2A as a therapeutic strategy for prostate cancer treatment.Roles of ceramide synthase and ceramide clearence genes in nilotinib-induced cell death in chronic myeloid leukemia cells.Serine palmitoyltransferase inhibitor myriocin induces growth inhibition of B16F10 melanoma cells through G(2) /M phase arrest.Potentiation of cannabinoid-induced cytotoxicity in mantle cell lymphoma through modulation of ceramide metabolism.Ceramide in the prostate.Ceramide synthase 1 is regulated by proteasomal mediated turnoverA general and concise asymmetric synthesis of sphingosine, safingol and phytosphingosines via tethered aminohydroxylation.Preparation of anti-vicinal amino alcohols: asymmetric synthesis of D-erythro-sphinganine, (+)-spisulosine, and D-ribo-phytosphingosine.Myriocin, a serine palmitoyltransferase inhibitor, suppresses tumor growth in a murine melanoma model by inhibiting de novo sphingolipid synthesis.Large-scale purification and characterization of recombinant Pseudomonas ceramidase: regulation by calcium.Profiling circRNA and miRNA of radiation-induced esophageal injury in a rat model
P2860
Q24657499-BBCB71F4-BF2A-422F-A70F-6FFB9B2F3E59Q27015257-3879F715-A7A4-49B7-A493-4290FE3B7ED3Q27933657-2F31A416-B358-49DA-8EE1-B6E87A8D392EQ28082709-08EE331B-E9E0-402F-99BF-FA7FCEC5410FQ28590499-FCD69979-D0E8-46C3-81CC-67168E05B840Q28655507-6B4D63E9-5A3F-485C-959C-FF253FACC94CQ33730375-6E21603B-FB69-4507-9CA2-6EF78CF55CBDQ33733991-E9336F27-93C5-45AF-9AC3-901FBF9DBEB5Q34453596-9D0BC37C-9957-4CEE-952A-CDA000BAD4DBQ34568452-537EEC1D-C378-4245-B331-C27DDB4BF4F8Q35057879-7A79A15B-7045-48D4-8EAE-C3C9CAE945ACQ35149929-EA0BB27D-4E27-4BD5-8F8A-69F3ABBE2CAAQ35149996-1E40E64B-E0BF-4B81-8340-DA9D1960A2F6Q35831148-BD2EF38D-F840-4287-BAB2-F8A308355D94Q36592826-A4AC0DD6-1A3F-4CCC-ABD2-3176978E952DQ36658347-059B0B09-213B-4A25-8E32-BE994FE08B0CQ36803735-1BB79C30-F1B3-4B09-8E7E-A8C3B33A0FCEQ36902769-560D4749-E991-436B-9498-D341259AA839Q37458377-040BA08F-8EDE-4310-A026-2F5FA69DBFEEQ37765497-7A56BD3A-B76E-431A-BFAD-D18913BA410CQ37802552-DF5E5325-8CAF-47C3-AD12-9F17B8A36A1DQ37874939-337878B0-8853-4CDF-A19F-BD93A1187FD5Q38071694-F572218C-DAB7-49C9-808C-DB89CF4E6A88Q38089154-45B1F34C-F77B-48A4-8292-7575A9DBEDC4Q38505682-F970DFFF-F810-4960-A4C0-2AAB108022C1Q38915115-F84FD75F-7504-488C-9A01-F102F1B9FEADQ39097201-D34E039B-83A3-43A3-95A1-3EAD94807C27Q39506935-A26C1A63-A3F6-499A-89C8-968C6AEE1D9DQ39529973-695853B5-976D-46F8-A6BE-62EA843FAC6DQ39824459-26C3CC40-67C0-495E-A838-3C741294A393Q41960726-DB2A6363-8E3E-44A6-AA94-D51B3CEED24CQ42452797-FA9CAA54-1984-4B57-A191-1CBFAD152D3BQ42906170-0390A122-C1F2-4CD0-BBD9-46D45C4DE8D6Q43080758-2DDF61C0-BF0F-41C3-BCB4-2A5B60A5ACD0Q53185416-B3637E8F-883F-4D8A-9E67-2E91F63F6D57Q54450465-5D7F3DC2-E4FF-483B-B9CA-2CB1D78575E6Q57050214-A2BF4D83-2D47-4D16-8A3D-3A5FE430090B
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Sphingolipid targets in cancer therapy.
@ast
Sphingolipid targets in cancer therapy.
@en
type
label
Sphingolipid targets in cancer therapy.
@ast
Sphingolipid targets in cancer therapy.
@en
prefLabel
Sphingolipid targets in cancer therapy.
@ast
Sphingolipid targets in cancer therapy.
@en
P2093
P1476
Sphingolipid targets in cancer therapy.
@en
P2093
David E Modrak
David M Goldenberg
David V Gold
P304
P356
10.1158/1535-7163.MCT-05-0420
P577
2006-02-01T00:00:00Z